WebNov 4, 2024 · Chinook will host a live conference call and webcast today at 4:30 pm EDT to discuss the data from Cohort 1 of Part 3 of Chinook’s ongoing phase 1/2 study of BION-1301 in patients with IgAN as well as the atrasentan posters that were presented at ASN Kidney Week 2024. WebBION-1301, a potentially disease-modifying anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial of patients with IgA nephropathy. Learn More
Chinook Therapeutics Announces the Appointment of Robert
Web2 days ago · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a … Web1 day ago · The MarketWatch News Department was not involved in the creation of this content. SEATTLE, April 13, Apr 13, 2024 (GLOBE NEWSWIRE via COMTEX) -- … canadian tire gas bar midland ontario
Chinook Therapeutics Announces the Appointment of Robert W.
WebMar 30, 2024 · Cantor analyst Emma Nealon says that an abstract of Chinook Therapeutics' (NASDAQ: KDNY) BION-1301 in IgA nephropathy (kidney disease) to be presented at … WebDec 8, 2024 · BION-1301 is a first-in-class humanized antibody targeting APRIL (TNFSF13). We demonstrated that BION-1301 inhibits proliferation and survival of tumor cells and alleviates both APRIL-mediated drug resistance and immune suppression in preclinical multiple myeloma (MM) models 1.BION-1301 inhibits ligand dependent activation of both … WebNov 18, 2024 · Another compound in development at Chinook, BION-1301, is also in Phase II. It tackles IgAN earlier in its development when it sees galactose-deficient IgA molecules. “The molecules are aberrant, so the patient’s immune system reacts by creating IgG antibodies that bind together and create immune complexes. canadian tire gas bar winnipeg